|Articles|October 2, 2015
- BioPharm International-10-15-2015
- Volume 2015 eBook
- Issue 2
Aseptic Processing for Cytotherapy, Regenerative Medicine, and Tissue-Engineered Products
Author(s)Mamoru Kokubo, James E. Akers
Isolators offer a safety and economic advantage for next-generation regenerative medicine products.
Advertisement
BioPharm International
eBooks Volume 28, Issue 14
Manufacturing advanced biologics demands solutions that are quite different from what is being used for large-scale industrial biologics processing today. This article touches on approaches that work with advanced biologics. Read this article and other articles in
BioPharm International
's 2015
eBook.
Articles in this issue
about 10 years ago
Fluctuating Capacity and Demand Conditions in Biomanufacturingabout 10 years ago
Cleaning Validation for Biologicsabout 10 years ago
Automation of Single-Use Systemsabout 10 years ago
Are Biopharma Patents Poised on the Post-Grant Chopping Block?about 10 years ago
Raising the Bar for Biopharma TrainingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
